Jubilant Pharmova, a company in the Pharmaceuticals industry, reported revenue of ₹2,370 crore and net profit of ₹31 crore for the September 2026 quarter.
Jubilant Pharmova (NSE: JUBLPHARMA) closed at ₹935.05 on 20 Nov 2026, down 13.4% over the past year. Its market capitalisation is ₹14,895 crore and it trades at 50.4 times earnings.
Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.